Literature DB >> 19556961

Tumor biomarkers in melanoma.

Selma Ugurel1, Jochen Utikal, Jürgen C Becker.   

Abstract

BACKGROUND: Morphologic and histopathologic markers have been the backbone for the classification and prognostic assessment of melanoma. Availability of an increasing number of molecular markers, however, provides the potential for refining diagnostic and prognostic categories in this disease.
METHODS: We reviewed the recent data that are accumulating concerning gene expression and genetic profiling and related these to clinical aspects of the disease.
RESULTS: Multiple biomarkers have now been described, and their biologic significance is being established. In addition, several candidate molecules involved in melanoma pathogenesis have been identified.
CONCLUSIONS: The process of biomarker identification and validation is providing a rapidly changing molecular view of melanoma, a strategy that is necessary for developing truly stratified or even personalized prevention or management.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19556961     DOI: 10.1177/107327480901600303

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  10 in total

Review 1.  [Treatment of advanced metastatic melanoma].

Authors:  S Ugurel; J C Becker
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

Review 2.  Circulating serologic and molecular biomarkers in malignant melanoma.

Authors:  Shanique R Palmer; Lori A Erickson; Ilia Ichetovkin; Daniel J Knauer; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

3.  A novel biomarker harvesting nanotechnology identifies Bak as a candidate melanoma biomarker in serum.

Authors:  Caterina Longo; Guido Gambara; Virginia Espina; Alessandra Luchini; Barney Bishop; Alexis S Patanarut; Emanuel F Petricoin; Francesca Beretti; Barbara Ferrari; Enrico Garaci; Anto De Pol; Giovanni Pellacani; Lance A Liotta
Journal:  Exp Dermatol       Date:  2011-01       Impact factor: 3.960

4.  Characterization of a new human melanoma cell line with CD133 expression.

Authors:  Rosario Gil-Benso; Carlos Monteagudo; Miguel Cerdá-Nicolás; Robert C Callaghan; Sandra Pinto; Alicia Martínez-Romero; Ana Pellín-Carcelén; Teresa San-Miguel; Juan C Cigudosa; Concha López-Ginés
Journal:  Hum Cell       Date:  2012-04-13       Impact factor: 4.174

5.  Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.

Authors:  Athanassios Kyrgidis; Thrasivoulos-George Tzellos; Stefanos Triaridis
Journal:  J Carcinog       Date:  2010-04-01

6.  IL-8 and cathepsin B as melanoma serum biomarkers.

Authors:  Hongtao Zhang; Ting Fu; Suzanne McGettigan; Suresh Kumar; Shujing Liu; David Speicher; Lynn Schuchter; Xiaowei Xu
Journal:  Int J Mol Sci       Date:  2011-02-25       Impact factor: 5.923

7.  Proteomics in melanoma biomarker discovery: great potential, many obstacles.

Authors:  Michael S Sabel; Yashu Liu; David M Lubman
Journal:  Int J Proteomics       Date:  2011-10-11

8.  Injectable hydrogels of newly designed brush biopolymers as sustained drug-delivery vehicle for melanoma treatment.

Authors:  Aparna Shukla; Akhand Pratap Singh; Pralay Maiti
Journal:  Signal Transduct Target Ther       Date:  2021-02-15

9.  Silencing of diphthamide synthesis 3 (Dph3) reduces metastasis of murine melanoma.

Authors:  Lei Wang; Yu Shi; Peijun Ju; Rui Liu; Siok Ping Yeo; Yinyan Xia; Hamed Owlanj; Zhiwei Feng
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

10.  Microbiopsy engineered for minimally invasive and suture-free sub-millimetre skin sampling.

Authors:  Lynlee L Lin; Tarl W Prow; Anthony P Raphael; Robert L Harrold Iii; Clare A Primiero; Alexander B Ansaldo; H Peter Soyer
Journal:  F1000Res       Date:  2013-05-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.